Patient population description
| Dendritics cell vaccine (n = 8) | Observation (n = 7) | |
|---|---|---|
| Age (mean, CI 95%) | 58.75 (52.25–65.25) | 56.29 (52.92–69.66) |
| Sex (%) | ||
| Male | 50% | 62.5% |
| Female | 50% | 37.5% |
| ECOG (median, range) | 0 (0–1) | 0 (0–1) |
| ESMO (median, range) | 1 (0–1) | 0 (0–1) |
| Köhne (median, range) | 0 (0–1) | 0 (0) |
| Nagashima score (%) | ||
| Low risk | 0% | 50% |
| Moderate risk | 33.33% | 50% |
| High risk | 66.67% | 0% |
| Fong score (%) | ||
| Low risk | 50% | 57.14% |
| High risk | 50% | 42.86% |
| Histology (%) | ||
| Adenocarcinoma | 87.5% | 100% |
| Mucinous | 12.5% | 0% |
| CEA (%) | ||
| < 200 ng/ml | 50% | 85.7% |
| > 200 ng/ml | 50% | 14.3% |
| Metastatic disease at diagnosis | 87.5% | 57.4% |
| Neoadjuvant cycles (mean, CI 95%) | 5.75 (4.68–6.82) | 6.57 (5.67–7.47) |
| KRAS status | ||
| Mutant | 62.5% | 57.14% |
| Wild type | 37.5% | 42.6% |
| MSI status | 37.5% | 0% |